Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 518 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Rash Clear all
Completed No phase listed Observational Accepts healthy volunteers

Potential Research Study Participant Registry

NCT00710489
View directory record Official record
Conditions
Acne, Actinic Keratosis, Dysplastic Nevi, Eczema, Psoriasis, Skin Cancer, Rosacea, Leg Ulcers, Foot Ulcers, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effectiveness and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne.

NCT02698436
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Acne Mask, 2.5% Benzoyl Peroxide Treatment
Device · Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
12 Years to 40 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Albuquerque, New Mexico • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris

NCT02661958
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-1, S6G5T-5, S6G5T-6, S6G5T-7, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Anaheim, California • Cerritos, California • Chula Vista, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 30, 2026, 5:47 PM EDT
Not listed Phase 2 Interventional

Evaluating LP-10 in Subjects With OLP

NCT06233591
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
LP-10 (Liposomal Tacrolimus)
Drug
Lead sponsor
Lipella Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Fremont, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

NCT01182636
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, Differin®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

NCT00689117
View directory record Official record
Conditions
Acne Vulgaris, Acne
Interventions
CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin), Vehicle Gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
1,649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Not applicable Interventional

Evaluation of the Safety and Efficacy of an Acne Treatment Device

NCT06420804
View directory record Official record
Conditions
Mild to Moderate Acne
Interventions
ZIIP Acne Treatment Device
Device
Lead sponsor
ZIIP Beauty
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pleasant Hill, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

NCT05188521
View directory record Official record
Conditions
Cutaneous Lichen Planus
Interventions
Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

NCT02682264
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01 cream, 1%
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
39
States / cities
Fort Smith, Arkansas • Little Rock, Arkansas • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 4 Interventional

The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

NCT06012448
View directory record Official record
Conditions
Dermal Hypersensitivity Reaction
Interventions
Dupilumab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris

NCT02656485
View directory record Official record
Conditions
Acne Vulgaris
Interventions
B244, Placebo
Drug
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

NCT02720627
View directory record Official record
Conditions
Acne Vulgaris
Interventions
cortexolone 17α-propionate
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years to 11 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Fort Smith, Arkansas • San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 30, 2026, 5:47 PM EDT
Terminated Not applicable Interventional

UVA1 Light for Scleroderma and Similar Conditions

NCT00476697
View directory record Official record
Conditions
Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
Interventions
German manufactured UVA1 emitting light system
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 30, 2026, 5:47 PM EDT
Withdrawn Not applicable Interventional

Acne Scarring in Skin of Color: Laser vs Microneedling

NCT03395678
View directory record Official record
Conditions
Acne Vulgaris, Scar
Interventions
Microneedling, Fractional non-ablative 1,540nm laser
Device
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash

NCT06015217
View directory record Official record
Conditions
Diaper Rash
Interventions
"Cetaphil Healing Ointment"
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Months to 24 Months
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

NCT02849860
View directory record Official record
Conditions
Acne
Interventions
IDP-121 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

NCT04214639
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, IDP-126 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Bryant, Arkansas • Fremont, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 30, 2026, 5:47 PM EDT
Not listed Phase 2 Interventional

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

NCT02395549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
0.375% (w/w) MTC896 Gel, 0.75% (w/w) MTC896 Gel, 1.5% (w/w) MTC896 Gel, Vehicle Control Gel
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
16 Years to 65 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 30, 2026, 5:47 PM EDT
Terminated No phase listed Observational

Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin

NCT01466504
View directory record Official record
Conditions
Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma
Interventions
skin punch biopsy
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 30, 2026, 5:47 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluating Microneedling With CBD and Hempseed Oil for Acne Vulgaris Safety and Efficacy

NCT06362889
View directory record Official record
Conditions
Acne Vulgaris (Disorder)
Interventions
Microneedling with CBD
Combination Product
Lead sponsor
Rejuva Medical Aesthetics
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 30, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

NCT02801903
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 16 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 30, 2026, 5:47 PM EDT
Terminated Phase 4 Interventional Results available

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

NCT02500147
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 30, 2026, 5:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris

NCT01929057
View directory record Official record
Conditions
Acne
Interventions
Skin biopsy, Blood draw
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 30, 2026, 5:47 PM EDT